Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.
To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link
The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
- Target Disease Indication
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Lupus Nephritis
- Melanoma
- Multiple Myeloma
- Primary Sjögren's Syndrome
- Others
- Target Immune Checkpoint
- B7-H3
- CD38
- CD40
- CD47
- Others
- Mechanism of Action
- Inhibitory
- Stimulatory
- Therapeutic Modality
- Monoclonal Antibody
- Small Molecule
- Type of Therapy
- Monotherapy
- Combination Therapy
- Route of Administration
- Intravenous
- Subcutaneous
- Others
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific and the Rest of the World
The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Bristol Myers Squibb
- GlaxoSmithKline
- Incyte
- Novartis
- Trillium Therapeutics
Table of Contents
- Preface
2. Executive Summary
Introduction
- Current Market Landscape: Clinical and Preclinical Molecules
- Market Landscape: Therapies Targeting Cd47
- Market Landscape: Therapies Targeting 4-1bb
- Clinical Trial Analysis
- Company Profiles: Next Generation Inhibitors and Stimulators
- Academic Grants Analysis
- Partnerships and Collaborations
- Target Competitiveness Analysis
- Big Pharma Initiatives
- Market Forecast and Opportunity Analysis
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415